Pralatrexate

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 216 publications

Pembrolizumab and pralatrexate for relapsed or refractory peripheral T-cell lymphomas.

Pembrolizumab and pralatrexate for relapsed or refractory peripheral T-cell lymphomas.

Journal: British journal of haematology

Published: December 22, 2025

Integrating functional genomics and proteomics identifies Folate Carrier SLC19A1 as a predictor of pralatrexate sensitivity in T-cell lymphoma.

Integrating functional genomics and proteomics identifies Folate Carrier SLC19A1 as a predictor of pralatrexate sensitivity in T-cell lymphoma.

Journal: bioRxiv : the preprint server for biology

Published: November 24, 2025

Subcutaneous panniculitis-like T-cell lymphoma complicated by hemophagocytic syndrome with significant response to pralatrexate: A case report.

Subcutaneous panniculitis-like T-cell lymphoma complicated by hemophagocytic syndrome with significant response to pralatrexate: A case report.

Journal: JAAD case reports

Published: November 10, 2025

Case series of long-term responders to pralatrexate in peripheral T-cell lymphoma.

Case series of long-term responders to pralatrexate in peripheral T-cell lymphoma.

Journal: Journal of clinical and experimental hematopathology : JCEH

Published: June 29, 2025

Inhibition Of One-Carbon Metabolism In Ewing Sarcoma Results In Profound And Prolonged Growth Suppression Associated With Purine Depletion.

Inhibition Of One-Carbon Metabolism In Ewing Sarcoma Results In Profound And Prolonged Growth Suppression Associated With Purine Depletion.

Journal: bioRxiv : the preprint server for biology

Published: May 16, 2025

One-Carbon Metabolism Inhibition Depletes Purines and Results in Profound and Prolonged Ewing Sarcoma Growth Suppression.

One-Carbon Metabolism Inhibition Depletes Purines and Results in Profound and Prolonged Ewing Sarcoma Growth Suppression.

Journal: Cancer research communications

Published: April 24, 2025

Pralatrexate effectively inhibits the replication of monkeypox virus in vitro and in vivo.

Pralatrexate effectively inhibits the replication of monkeypox virus in vitro and in vivo.

Journal: Antiviral research

Published: April 14, 2025

Pralatrexate is effective in cytotoxic cutaneous T-cell lymphomas.

Pralatrexate is effective in cytotoxic cutaneous T-cell lymphomas.

Journal: Blood advances

Published: March 28, 2025

Design of a Phase I Drug Combination Study with Adaptive Allocation Based on Dose-Limiting Toxicity Attribution.

Design of a Phase I Drug Combination Study with Adaptive Allocation Based on Dose-Limiting Toxicity Attribution.

Journal: Cancers

Published: January 31, 2025

Pralatrexate represses the resistance of HCC cells to molecular targeted agents via the miRNA-34a/Notch pathway.

Pralatrexate represses the resistance of HCC cells to molecular targeted agents via the miRNA-34a/Notch pathway.

Journal: Discover oncology

Published: July 26, 2024

US Food and Drug Administration's Directive to Deal With Delayed Confirmatory Trials: Lessons From Pralatrexate and Belinostat for T-Cell Lymphoma.

US Food and Drug Administration's Directive to Deal With Delayed Confirmatory Trials: Lessons From Pralatrexate and Belinostat for T-Cell Lymphoma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 25, 2024

Pralatrexate injection combined with oral leucovorin for mucositis management in PTCL/CTCL treatment: a multicenter phase 2 trial.

Pralatrexate injection combined with oral leucovorin for mucositis management in PTCL/CTCL treatment: a multicenter phase 2 trial.

Journal: Blood neoplasia

Published: July 01, 2024

Showing 1-12 of 216

Last Updated: 04/28/2026